Primary objective:

To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD)

Secondary objective:

Improvement of Fasting blood glucose (FPG) after 4 months treatment (% of patients treated to target HbA1c ≤7.0% and/or FBG≤6.0mmol/L). Frequency of hypoglycemic episodes, quality of life with basal+ OAD regimen.

Inclusion Criteria:

• Patients with Type 2 Diabetes Mellitus inadequately controlled at least 3 months on premixed insulin with 1 or 2 OADs
• 7.5 ≤ HbA1c ≤ 9.5%
• FPG ≥6.7 mmol/L
• History of Diabetes mellitus ≤10 years
• Premix insulin daily dosage ≤ 50 IU/Day

Exclusion Criteria:

• Type 1 Diabetes Mellitus
• Former treated on TZD
• Pregnancy / Lactation
• Creatine ≥1.5 mg/dl
• Hepatic disease, jaundice,or ALT/AST≥ 2.5 times of normal range
• Hormone therapy,
• Acute status of Diabetes complications
• Severe concomitant disease or complications with high risk of unexpected fatal events, like Myocardial Infarct, stroke, heart failure.
• Allergic to insulin glargine or any ingredient
• Participation in another clinical trial within 3 months

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.